Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Lilly to close Surrey neuroscience research site
by Lisa M. Jarvis
October 19, 2019
| A version of this story appeared in
Volume 97, Issue 41
As part of a review of its R&D network, Eli Lilly and Company will close its neuroscience research center in Surrey, England, by the end of 2020. According to Lilly, consolidation over the years has left the site with fewer than 45 neuroscientists and 35 chemists. Remaining neuroscience activities will be shifted to the firm’s site in Cambridge, Massachusetts, while a small number of staffers will move to its Indianapolis research hub. The closure is expected to cost 80 of the 270 jobs in Surrey.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X